Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study

被引:2
|
作者
Qiu, Xianxin [1 ,2 ,3 ,4 ]
Gao, Jing [1 ,2 ,4 ]
Yang, Jing [1 ,2 ,4 ]
Hu, Jiyi [1 ,2 ,4 ]
Hu, Weixu [1 ,2 ,4 ]
Huang, Qingting [1 ,2 ,4 ]
Kong, Lin [2 ,3 ,4 ]
Lu, Jiade J. [1 ,2 ,4 ]
机构
[1] Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Shanghai, Peoples R China
[2] Shanghai Engn Res Ctr Proton & Heavy Ion Radiat T, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Canc Ctr, Shanghai, Peoples R China
[4] Shanghai Key Lab Radiat Oncol 20dz2261000, Shanghai, Peoples R China
关键词
Glioblastoma (GBM); anaplastic astrocytoma (AA); carbon ion radiotherapy; proton radiotherapy; temozolomide; GLIOBLASTOMA-MULTIFORME; RESPONSE ASSESSMENT; CELL-LINES; TEMOZOLOMIDE; THERAPY; PHOTON; INDUCTION; CRITERIA; TUMORS; BEAMS;
D O I
10.21037/atm-20-7750
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the maximal tolerated dose (MTD) of a carbon-ion radiotherapy (CIRT) boost prior to standard dose proton radiotherapy (PRT) for newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) patients with residual lesion after resection. Methods: In total, 18 patients with high-grade glioma (HGG) (16 with GBM and 2 with AA) were enrolled in a prospective 3??3 design phase 1 trial. We investigated four dose-levels of CIRT boost [9 (starting level), 12, 15, and 18 Gy relative biological effectiveness (RBE)] delivered in three equal fractions prior to the standard dose PRT (60 Gy RBE in 30 fractions). Concurrent temozolomide (TMZ) was not provided during the CIRT boost but was initiated on the first day of PRT. Acute and late toxicities were scored based on the Common Terminology Criteria for Adverse Events (CTCAE, v 4.03). Dose-limiting toxicities (DLTs) were defined as radiation-induced severe toxicities (>_ grade 3). Results: With a median follow-up of 17.9 months, no severe (>_ grade 3) acute or late toxicities were observed in patients treated with the first three dose levels (CIRT boost doses of 9, 12, 15 Gy RBE). Severe late toxicity (grade 3 radiation necrosis) was observed in the first patient treated with the 18 Gy RBE CIRT boost level. Therefore, this trial was terminated and the MTD of the induction CIRT boost was determined at 15 Gy RBE in 3 fractions. At the time of this analysis, both patients with AA were alive without disease progression. The progression-free survival (PFS) and overall survival (OS) for GBM at 12 months were 50.6% and 78.6%, respectively. Conclusions: Particle beam radiotherapy consisting of a CIRT boost of 15 Gy RBE (in 3 fractions) following standard dose PRT (60 Gy RBE in 30 fractions), and used in conjunction with TMZ, is safe and potentially effective for patients with HGG.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: A phase I/II dose-escalation study
    Tsuji, Hiroshi
    Ishikawa, Hitoshi
    Yanagi, Takeshi
    Hirasawa, Naoki
    Kamada, Tadashi
    Mizoe, Jun-Etsu
    Kanai, Tatsuaki
    Tsujii, Hirohiko
    Ohnishi, Yoshitaka
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03): : 857 - 862
  • [22] Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma
    Patil, Vijay M.
    Bhelekar, Arti
    Menon, Nandini
    Bhattacharjee, Atanu
    Simha, Vijai
    Abhinav, Ram
    Abhyankar, Anuja
    Sridhar, Epari
    Mahajan, Abhishek
    Puranik, Ameya D.
    Purandare, Nilendu
    Janu, Amit
    Ahuja, Ankita
    Krishnatry, Rahul
    Gupta, Tejpal
    Jalali, Rakesh
    CANCER MEDICINE, 2020, 9 (13): : 4676 - 4685
  • [23] Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
    A F Hottinger
    A B Aissa
    V Espeli
    D Squiban
    N Dunkel
    M I Vargas
    T Hundsberger
    N Mach
    K Schaller
    D C Weber
    A Bodmer
    P-Y Dietrich
    British Journal of Cancer, 2014, 110 : 2655 - 2661
  • [24] Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
    Hottinger, A. F.
    Aissa, A. B.
    Espeli, V.
    Squiban, D.
    Dunkel, N.
    Vargas, M. I.
    Hundsberger, T.
    Mach, N.
    Schaller, K.
    Weber, D. C.
    Bodmer, A.
    Dietrich, P-Y
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2655 - 2661
  • [25] A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
    Lawrence, Yaacov R.
    Porper, Keren
    Shpatz, Yael
    Plotkin, Luba
    Pechthold, Ronit
    Talianski, Alisa
    Symon, Zvi
    Amit, Uri
    Cohen, Zvi
    Gnessin, Hili
    Anikster, Yair
    Mardor, Yael
    Zach, Leor
    CANCER RESEARCH, 2021, 81 (13)
  • [26] A phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
    Lawrence, Yaacov
    Porper, Keren
    Shpatz, Yael
    Amit, Uri
    Symon, Zvi
    Zach, Leor
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [27] Phase 1 and pharmacokinetic studies of erlotinib administered concurrently with and after radiotherapy for children, adolescents, and young adults with high-grade glioma
    Broniscer, Alberto
    Clinton, Stewart
    Baker, Suzanne
    Merchant, Thomas
    Laningham, Fred
    Schaiquevich, Paula
    Mehmet, Kocak
    Morris, Brannon
    Sanders, Robert
    Kun, Larry
    Ellison, David
    Gajjar, Amar
    NEURO-ONCOLOGY, 2008, 10 (03) : 512 - 512
  • [28] Improved risk stratification via integration of radiomics and dosiomics features in patients with recurrent high-grade glioma undergoing carbon ion radiotherapy (CIRT).
    Salome, Patrick
    Sforazzini, Francesco
    Kudak, Andreas
    Koenig, Laila
    Kickingereder, Philipp
    Bougatf, Nina
    Wick, Wolfgang
    Jaekel, Oliver
    Debus, Juergen
    Knoll, Maximilian
    Abdollahi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Phase I dose-escalation trial of S-1 combined with carbon-ion radiotherapy for sinonasal squamous cell carcinoma
    Takahashi, Daiki
    Demizu, Yusuke
    Park, Sung Chul
    Matsuo, Yoshiro
    Sulaiman, Nor Shazrina
    Terashima, Kazuki
    Tokumaru, Sunao
    Akashi, Masaya
    Okimoto, Tomoaki
    JOURNAL OF RADIATION RESEARCH, 2020, 61 (05) : 733 - 739
  • [30] High-dose radiation therapy using photons and carbon Ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon Ion radiotherapy
    Combs, S. E.
    Hartmann, C.
    Schulz-Ertner, D.
    von Deimling, A.
    Debus, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 123 - 123